Saturday 04 February 2012
Headlines
Did you find this story interesting? (0) (0)
23/02/2009 02:08:05
France-New Vaccine for bird flu.
Scientists on Sunday unveiled lab-made human antibodies that can disable several types of influenza, including highly-lethal H5N1 bird flu and the "Spanish Flu" strain that killed tens of millions in 1918.
Tested in mice, the antibodies work by binding to a previously obscure structure in the flu virus which, when blocked, sabotages the pathogen’s ability to enter the cell it is trying to infect, according to the study.
Because this structure -- described by one scientist as a "viral Achilles’ heel" -- is genetically stable and has resisted mutation over time, the antibodies are effective against many different strains.
The breakthrough "holds considerable promise for further development into a medical tool to treat and prevent seasonal as well as pandemic influenza," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which helped fund the study.
Clinical trials on humans could begin within a couple of years, the researchers said.
Seasonal flu kills more than 250,000 people every year, and pandemic flu, which occurs with the emergence of deadly viral strains against which people lack immunity, remains an ever-present threat.
Vaccines have long been the first line of defense against flu, but even seasonal viruses evolve so rapidly that the vaccines need to be updated every year. Even then, they are not always effective.
A team led by Wayne Marasco, a professor at Harvard Medical School, began the study by scanning tens of billions of so-called monoclonal antibodies in the laboratory.
Antibodies, produced by the immune system’s white blood cells, are highly specialised proteins that seek out and bind to other large molecules, called antigens, found on the surface of an invading bacteria or virus.
Once locked in, an antibody serves as a beacon to immune cells that attack the pathogens. More rarely, it can disable a disease agent all by itself.
Monoclonal antibodies are manufactured in the laboratory from a single parent cell using a technique devised more than 30 years ago.
In cancer treatment, they help the immune system zero in on the right target.
Marasco and colleagues turned up 10 of the artificial antibodies that bound to the H5N1 avian flu, said the study, published in the Nature Group’s journal Nature Structural and Molecular Biology.
In further experiments with mice, the scientists found that three of these monoclonal antibodies neutralised 10 of 16 known influenza "A" viruses, including H5N1.
To date, only persons in close contact with infected fowl have become infected with this deadly strain. But scientists fear that a future mutation could "jump species" and become easily transmissible among humans.
These were startling results. Not only had a single type of antibody honed in on different strains of virus, it had disarmed the pathogens on its own without having to call in immune system reinforcements.
To find out how this was possible, Marasco teamed up with researchers at the Infectious and Inflammatory Disease Center in La Jolla, California to analyse the atomic structure of one of the antibodies.
They discovered that by latching onto a poorly understood part of a lollipop-shaped protein -- called hemagglutin (HA) -- on the surface of the virus, the lab-made antibody had disabled the pathogen’s capacity to change shape and thus enter into the host cell.
"We believe ... the hemagglutin protein acts as a decoy by constantly undergoing mutation and thereby attracting the immune system to produce antibodies against it rather than against the pocket in the neck of the protein," Marasco said a statement.
In a commentary, also published by Nature, Taia Wang and Peter Palese of the Mount Sinai School of Medicine in New York said the study had uncovered "a viral Achilles’ heel" that is resistant to genetic variation.
The new findings "brings us closer to the development of a universal influenza virus vaccine," they said.
Tested in mice, the antibodies work by binding to a previously obscure structure in the flu virus which, when blocked, sabotages the pathogen’s ability to enter the cell it is trying to infect, according to the study.
Because this structure -- described by one scientist as a "viral Achilles’ heel" -- is genetically stable and has resisted mutation over time, the antibodies are effective against many different strains.
The breakthrough "holds considerable promise for further development into a medical tool to treat and prevent seasonal as well as pandemic influenza," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which helped fund the study.
Clinical trials on humans could begin within a couple of years, the researchers said.
Seasonal flu kills more than 250,000 people every year, and pandemic flu, which occurs with the emergence of deadly viral strains against which people lack immunity, remains an ever-present threat.
Vaccines have long been the first line of defense against flu, but even seasonal viruses evolve so rapidly that the vaccines need to be updated every year. Even then, they are not always effective.
A team led by Wayne Marasco, a professor at Harvard Medical School, began the study by scanning tens of billions of so-called monoclonal antibodies in the laboratory.
Antibodies, produced by the immune system’s white blood cells, are highly specialised proteins that seek out and bind to other large molecules, called antigens, found on the surface of an invading bacteria or virus.
Once locked in, an antibody serves as a beacon to immune cells that attack the pathogens. More rarely, it can disable a disease agent all by itself.
Monoclonal antibodies are manufactured in the laboratory from a single parent cell using a technique devised more than 30 years ago.
In cancer treatment, they help the immune system zero in on the right target.
Marasco and colleagues turned up 10 of the artificial antibodies that bound to the H5N1 avian flu, said the study, published in the Nature Group’s journal Nature Structural and Molecular Biology.
In further experiments with mice, the scientists found that three of these monoclonal antibodies neutralised 10 of 16 known influenza "A" viruses, including H5N1.
To date, only persons in close contact with infected fowl have become infected with this deadly strain. But scientists fear that a future mutation could "jump species" and become easily transmissible among humans.
These were startling results. Not only had a single type of antibody honed in on different strains of virus, it had disarmed the pathogens on its own without having to call in immune system reinforcements.
To find out how this was possible, Marasco teamed up with researchers at the Infectious and Inflammatory Disease Center in La Jolla, California to analyse the atomic structure of one of the antibodies.
They discovered that by latching onto a poorly understood part of a lollipop-shaped protein -- called hemagglutin (HA) -- on the surface of the virus, the lab-made antibody had disabled the pathogen’s capacity to change shape and thus enter into the host cell.
"We believe ... the hemagglutin protein acts as a decoy by constantly undergoing mutation and thereby attracting the immune system to produce antibodies against it rather than against the pocket in the neck of the protein," Marasco said a statement.
In a commentary, also published by Nature, Taia Wang and Peter Palese of the Mount Sinai School of Medicine in New York said the study had uncovered "a viral Achilles’ heel" that is resistant to genetic variation.
The new findings "brings us closer to the development of a universal influenza virus vaccine," they said.
No Comments
Nobody has posted any comments on this story.
|
Farming items for Sale
|
New Holland TS115 - Darlington(GBP 15750)
Massey Ferguson 5455 - 4wd Tractor - Ayr(GBP 19500)
Case IH CX 100, Deluxe Cab, 2 wd - Ballyclare(GBP 12044)
New Holland TSA100 - Omagh(GBP 25200)
Valmet 6400 - Dalbeattie(GBP 9540)
Related News
Japan-New Bird Flu vaccine developed. - 29 Jan 2009JAPAN-NEW BIRD FLU VACCINE. Researchers in Japan said Thursday they had developed a flu vaccine that works against multiple viruses and could preven...
France-Bird flu. - 06 Feb 2009FRANCE - The veterinary authorities have sent a report to the World Organisation for Animal Health (OIE) regarding a first outbreak of low pathogenic ...
Switzerland-Bird Flu vaccine. - 26 Feb 2009SWITZERLAND-VACCCINE FOR BIRD FLU. The production capacity of bird flu vaccines has tripled since 2007 but it could still take up to four years to ...
Poland-Bird flu vaccine scam. - 08 Apr 2009WARSAW – Nine health workers went on trial in northern Poland Monday accused of having tested a vaccine against bird flu on nearly 200 patients withou...
United States-Bird flu vaccine. - 24 Apr 2009UNITED STATED-INROADS INTO BIRD FLU VACCINE. Important insights into how to combat the potentially lethal H5N1avian influenza virus have been provide...
Over 5,000 Birds Culled In Bird Flu Hit Tripura - 08 Apr 2008More than 5,000 poultry were culled Tuesday in Tripura as authorities ordered the slaughter of 25,000 birds after laboratory tests confirmed bird flu ...
250000 birds culled after bird flu outbreak in Assam - 15 Dec 2008India has culled at least 250,000 birds in Assam to contain an outbreak of bird flu among poultry, a government official said. At least 950 health ...
Hong Kong-Bird Flu in wild birds. - 17 Feb 2009HONG KONG – BIRD FLU. The carcasses of a goose and two ducks found on a beach have tested positive for the H5N1 subtype of the highly pathogenic av...
New bird flu scare - 56,000 ducks culled - 21 Nov 2007POULTRY was being culled on a sixth farm this afternoon amid another bird flu scare, the Department for the Environment, Food and Rural Affairs (De...
New bird flu outbreak in Poland - 13 Dec 2007Poland has been hit by a fresh outbreak of bird flu with the discovery of the deadly H5N1 virus at two poultry farms, veterinary authorities said on W...
